Histogen Inc (NASDAQ:HSTO) is a regenerative medicine company developing patented technologies designed to stimulate the bodyâs stem cells to regenerate tissues and restore youthful function. The Companyâs lead therapeutic product has induced hair growth in multiple clinical trials, addressing a multibillion dollar global market. Additional applications of Histogenâs technology span multiple therapeutic and aesthetic areas including skin care, orthopedics, wound healing, and dermal fillers. Histogen Inc., therapeutics are based on the products of fibroblast cells grown under simulated embryonic conditions. Offering HST-001, a hair stimulating complex in Phase 1b/2a clinical trial for treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrink
